# Effect of Tepotinib on PK of CYP3A Substrate Midazolam

> **NCT03628339** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Midazolam
- **DRUG:** Tepotinib

## Key facts

- **NCT ID:** NCT03628339
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-20
- **Primary completion:** 2018-10-25
- **Final completion:** 2018-10-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03628339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03628339, "Effect of Tepotinib on PK of CYP3A Substrate Midazolam". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03628339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*